With the rapid Health care reform and increasing cost-containment pressure on China's health care system, Chinese government authorities and hospital administrators have focus more attention on the importance on health economics to allocate the scarce resources more efficiently. OBJECTIVE: The purpose of this study was to identify key decision criterias and source of information that government officials, hospital administrators and physicians perceive as important in drug pricing and reimbursement process and establishing clinical practice guidelines respectively. Moreover, obstacles to using pharmacoeconomic evaluations in decision-making were also identified. METHODS: Data were gathered through a survey questionnaire administered to various members of Health Authorities, Health Insurance Bureaus, State Food and Drug Administrations and hospitals throughout China. There were 390 member organisations of which 65% responded. Factor analysis CANOVA and Chi-square test were applied. RESULTS: The findings indicated that current Health care policies/guidelines supplied by government authorities are considered the most important source of information in decision making (mean score 4.28) as opposed to clinical or industry input. Cost Effectiveness arguments are considered the most important decision criteria (mean score 4.22). Although there was interest in pharmacoeconomics, these studies in China were limited (90.2%) and insufficient pharmaeconomic knowledge among health administrators (89.0%). There were also difficulties in translating study results into practical health care administrative and clinical usage. CONCLUSIONS: With the increasing interest and need for Pharmacoeconomics in China's Health care decision-making, training would be helpful in assisting government officials and hospital staffs'knowledge to make cost-effective health care decision. Assessing global pharmaeconomic guidelines would also be useful to pursuing China's pharmaeconomics interest.